A study by researchers at the University of Colorado Cancer Center is evaluating an imaging method that can help protect normal, healthy lung tissue during radiotherapy treatment in lung cancer patients.
A collaborative study, initiated by researchers at the University of Colorado Cancer Center, is evaluating an imaging method that can help protect normal, healthy lung tissue during radiotherapy treatment in lung cancer patients.
Using advanced image analysis techniques, the scientists plan to use results from 4D CT scans to map areas of the lung that have retained normal function without the need for additional testing. According to investigator Yevgeniy Vinogradskiy, PhD, lead investigator and assistant professor in the Department of Radiation Oncology at the CU School of Medicine, “We used to treat the lungs as a homogenous organ, as if all areas were equally important. Now we know that's not true - there's regionally variant function. The idea of this clinical trial is to spare functional portions of the lung during radiation by using this new imaging modality to display lung function.”
The complication arises from the fact that lung tumors move with every single breath that patients make, which makes a static image clicked at a specific time a crude estimate of the tumor’s position. The 4D CT, on the other hand, clicks a series of images shot over time to capture images of the lung and the tumor at different phases of the patient’s breathing cycle. Using the “lung function” information, which is information on the functional lung tissue around the tumor, physicians can carefully target the radiation so the normal tissue is spared during the process. The ultimate objective is to improve the patient’s quality of life.
The most important advantage, according to Vinogradskiy, is that there’s no additional testing required. The researchers will use existing imaging data acquired as part of standard of care. The trial will enroll 70 patients and is expected to be completed in 3 years.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More